Clinical Trials Logo

Filter by:
NCT ID: NCT05547971 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics

Start date: September 2022
Phase:
Study type: Observational

This project focuses on the early prediction and diagnosis of radiation-induced brain injury in nasopharyngeal carcinoma patients. Based on the big data of imaging and serum metabonomics samples, combined with the machine learning analysis method, dynamic evolution mode of radio-metabolomics characteristics was analyzed . The potential internal relationship between brain structure and serum metabolic changes was explored, and the individualized prediction model was constructed to screen out the high-risk patients with brain injury after tumor radiotherapy, so as to provide reference for the diagnosis of radiation-induced brain injury caused by tumor. radiotherapy Intelligent diagnosis provides a new theoretical and practical basis.

NCT ID: NCT05547841 Recruiting - Pregnancy Clinical Trials

Normal Reference Value for Echocardiography in Chinese Han Pregnancies

Start date: September 1, 2022
Phase:
Study type: Observational

The First Hospital of China Medical University initiated a multi-center study on the reference range of echocardiography in Chinese Han Pregnancies to determine the reference range of echocardiography in the pregnant population and to promote the clinical application of echocardiography in the pregnant population, thereby offering the value of early evaluation and early diagnosis for cardiac structure and function in the pregnant population.

NCT ID: NCT05547282 Recruiting - Cancer Patients Clinical Trials

Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure

FL001
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Response was evaluated according to the Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST) : ORR-To evaluate the objective effective rate of LDRT combined with SFRT and immunotherapy in patients with malignant tumors after immunotherapy resistance without standard regimens. PFS-To evaluate the progression-free survival (PFS) of patients with advanced malignant tumors after LDRT combined with SFRT and immunotherapy without standard regimens after immunotherapy resistance.DCR-To evaluate the proportion of patients with optimal response to LDRT and SFRT combined with immunotherapy to achieve complete response, partial response, or disease control after no standard regimen was available for immunotherapy resistance.HRQoL, AE and sAE-Evaluation of health related quality of life and safety of post-LDRT combined with SFRT and immunotherapy in patients with malignant tumors. To evaluate the benefit of patients in this trial.

NCT ID: NCT05546866 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.

NCT ID: NCT05546346 Recruiting - Capsule Endoscopes Clinical Trials

Clinical Application of Wearable Magnet Tracking System for Capsule Endoscopes

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

The investigators developed a wearable magnet tracking system, which provided a non-invasive and high accuracy method for capsule endoscopes localization. Data fusion from multiple sensors expanded positioning range and proposed localization algorithm overcame shortcomings of existing systems. This clinical trial was conducted to verify effectiveness and stability of the tracking system.

NCT ID: NCT05546320 Recruiting - Migraine Clinical Trials

Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale

COMPETE
Start date: October 15, 2022
Phase: Phase 4
Study type: Interventional

Migraine attack is an episodic disorder that affects approximately 12% of the population. Previous studies have shown that 41-48% of migraineur have a combination of patent foramen ovale (PFO). Clinical observational studies have been linking medication therapies which include anticoagulation and anti-platelet therapy with the effectiveness in improving migraine symptoms and reducing the frequency of attacks in patients combined with a PFO. However, it has been unclear whether the effectiveness of anticoagulation or anti-platelet therapy outweigh the conventional migraine medication therapy, as a result, we designed a multi-center randomized clinical trial aiming to examine the effectiveness of anticoagulation versus anti-platelet versus migraine medication therapy in migraine patients with PFO and provide a clinical guidance for migraineur.

NCT ID: NCT05546255 Recruiting - Clinical trials for Triple Negative Breast Cancer

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

A prospective phase II study conducted at the Cancer Hospital Chinese Academy of Medical Sciences to compare the effectiveness of eribulin combined with lobaplatin in the treatment of recurrent or metastatic triple-negative breast cancer

NCT ID: NCT05546086 Recruiting - Clinical trials for Non-Alcoholic Fatty Liver Disease

BeijngFH Health Cohort Study

FHCS
Start date: April 18, 2022
Phase:
Study type: Observational

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

NCT ID: NCT05546060 Recruiting - Clinical trials for Hemophagocytic Lymphohistiocytosis

Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

Start date: July 1, 2022
Phase: Phase 1
Study type: Interventional

This study aimed to investigate the efficacy and safety of venetoclax combined with dexamethasone and etoposide as a salvage therapy for hemophagocytic lymphohistiocytosis.

NCT ID: NCT05545852 Recruiting - Clinical trials for Papillary Thyroid Cancer

A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the feasibility and safety of gasless transaxillary posterior endoscopic thyroidectomy (Resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) and open radical thyroidectomy (Resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) as the current standard surgical treatment mode in terms of feasibility and safety of radical thyroidectomy.